Journal
JOURNAL OF MEDICAL PRIMATOLOGY
Volume 39, Issue 2, Pages 123-128Publisher
WILEY-BLACKWELL PUBLISHING, INC
DOI: 10.1111/j.1600-0684.2010.00400.x
Keywords
chimpanzees; great apes; neutralizing antibodies; poliomyelitis; transmission
Categories
Funding
- Robert Koch-Institut, Berlin
- Brian Hare
- Max-Planck-Institute for Evolutionary Anthropology
- Leipzig
- Kim Hammond
- Falls Road Hospital
- Baltimore
- Maryland
Ask authors/readers for more resources
Background To understand immunological responses in chimpanzees vaccinated with live-attenuated vaccine (oral polio vaccine; OPV), serum neutralizing antibodies against poliovirus types 1, 2, and 3 were investigated over time. Methods The neutralizing antibody titers against poliovirus types 1, 2, and 3 were determined by microneutralization test using 100 ID(50) of poliovirus types 1, 2, and 3 (Sabin strains). Results Neutralizing antibodies against poliovirus types 1, 2, and 3 were detected in 85.7%, 71.4%, and 65% of the serum from 42 chimpanzees tested 9 years post-vaccination. The neutralizing antibody titers in chimpanzees were similar to the documented levels in human studies as an indicator of vaccine efficacy. Conclusions This study reveals persistence of neutralizing antibodies in chimpanzees for at least 9 years after vaccination with OPV. This first study in chimpanzees provides useful information for the evaluation of the success of vaccination with OPV in other captive apes.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available